In this article, we will take a look at some of the best biotech stocks that are currently offering attractive upside to investors.
On April 16, reports from J.P. Morgan’s biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength. Biopharma venture capital amounted to $5.2 billion in the first quarter of 2026, and licensing stood at $77.3 billion for the same period. The total biopharma M&A market was worth $15.6 billion for 19 deals. The six biopharma IPOs collected $1.8 billion, which was greater than the entire year 2025 tally. In medtech, venture funding totaled $2.2 billion across 66 rounds. Medtech M&A totaled $26.6 billion across 37 deals. IPO activity remained selective, with one IPO raising $600 million on Nasdaq.
The present market situation offers great opportunities for investors interested in making investments in biotechnology stocks. There is high activity in licensing and M&A deals, with venture capital going into late-stage ventures. Public market openings bring new possibilities. Licensing transactions on obesity and diabetes, along with the sourcing of assets originating from China, are becoming trends.
These trends indicate a change in strategic priorities in the biotech stock market. With that background, let’s explore our 10 Best Biotech Stocks with Highest Upside Potential.
Billion Photos/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we conducted a screening of U.S.-listed biotechnology companies with market capitalizations above $2 billion. Also, we only shortlisted stocks with at least 75% upside potential according to consensus, as of April 24 closing. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Corcept Therapeutics Inc. (NASDAQ:CORT)
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 best biotech stocks with highest upside potential.
On April 11, Corcept Therapeutics Inc. (NASDAQ:CORT) released the overall survival results from its Phase 3 ROSELLA study involving Lifyorli and nab-paclitaxel treatment for women with platinum-resistant ovarian cancer during the annual conference of the Society of Gynaecologic Oncology. The findings were concurrently published in The Lancet journal. The ROSELLA study achieved both of its primary objectives of overall survival and progression-free survival without compromising on safety. This backs our bullish views for the stock.
The combination of Lifyorli with nab-paclitaxel is now part of the National Comprehensive Cancer Network guidelines as a preferred treatment regimen. The drug received approval from the FDA in March 2026 for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Patients receiving Lifyorli with nab-paclitaxel showed 35% fewer chances of mortality. Median overall survival was 4.1 months higher. The patients had a 30% lower rate of disease progression. The combination therapy is safe. The common adverse effects include low levels of haemoglobin, neutrophils, fatigue, nausea, diarrhea, platelets, rash, and reduced appetite.
Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage pharmaceutical company that is involved in developing therapies for severe conditions. These include endocrinologic, oncologic, metabolic, and neurologic disorders. It is developing medicines that target hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis.
Hedge Fund Resource Center